Where the Map Misses the Signal: Reconciling Pelvic Anatomy and PSMA in Prostate Cancer Care

A contradiction you can measure

Which matters more when you are hunting prostate cancer: the topology of the lymphatic map or the brightness of a molecular beacon? It is a practical question with surprising clinical consequences. Surgeons are taught to respect anatomical templates: if you do not sample the internal iliac (hypogastric) nodes, your staging is incomplete, and you may leave disease behind. Molecular imagers and therapeutic pioneers follow a different logic: find the cells that light up the strongest and treat them with targeted radionuclides or intraoperative probes.

Those two truths coexist uneasily. On one hand, careful pelvic lymph node dissection that includes the internal iliac basin is essential for representative staging, because those nodes are frequently involved even when clinical exams and conventional imaging suggest no nodal disease. For example, internal iliac nodes may harbor metastases in as many as 58 percent of patients deemed cN0, and in roughly 19 percent they are the only positive nodal site. On the other hand, prostate specific membrane antigen, or PSMA, is a molecular beacon expressed 100 to 1,000 times higher in prostate adenocarcinoma than in benign prostate, and its expression rises further under androgen deprivation and in high-grade or castration resistant disease. That makes PSMA-based imaging and therapies powerful, but also dynamic and context dependent.

The tension is not accidental: it comes from two different ways of knowing cancer. One is topographic: where does it sit in the body, which lymph node stations are occupied, what will a scalpel or a radiation field need to cover? The other is spectroscopic: which cells express a target at a high enough level to be seen or killed by molecular tools? This essay argues that the future of precise prostate cancer care depends on treating staging as an integrated, time-sensitive mapping problem that brings anatomy and molecular signal into the same frame. To get there we must adopt new mental models, change when and how we measure, and harmonize nets and spotlights so that neither misses the disease the other can find.

---

Two epistemologies of disease: the net and the spotlight

Imagine you are fishing in a river. One approach is to cast a wide net across known channels where fish travel. The other is to use a spotlight from a boat at night and pick out the brightest flashes. Both work, but they solve different problems. The net is comprehensive across a defined geography; the spotlight is exquisitely sensitive to certain behaviors and traits.

Surgery and systematic lymph node dissection function like the net. An extended pelvic dissection that deliberately includes the internal iliac nodes captures an anatomical cross section of disease distribution. It is blunt but reliable: if a node contains tumor, it will be removed and examined. The operating room does not depend on what the tumor currently expresses; it depends on where the tumor is physically lodged.

PSMA-based imaging and therapeutics act like the spotlight. PSMA expression is amplified in aggressive and treatment-exposed tumors, which makes PSMA-targeted positron emission tomography and radio-ligand therapy extremely useful tools for detection and treatment. Their sensitivity and specificity for PSMA-high lesions are remarkable. However, the brightness of the spotlight changes: PSMA expression is not a static property. It increases with androgen deprivation therapy and with progression to castration resistant disease. Therefore the results you obtain with PSMA tools depend on when you look and what the tumor has been exposed to.

This leads to three practical frictions:

1. A negative PSMA scan is not the same thing as an absent nodal metastasis, particularly in early or untreated disease. Small-volume nodes may be below the detection threshold despite being anatomically present.
2. A rigid reliance on anatomical templates without molecular guidance risks overtreatment and missed therapeutic opportunities. Some nodes may be anatomically involved but molecularly silent, while others may be small but PSMA-bright and therefore ideal targets for focal therapy.
3. Timing matters because therapy changes the landscape. Androgen deprivation can increase PSMA expression and reveal previously occult disease, but this revelation comes after you have already altered the biology of the tumor.

Understanding those frictions is the first step toward a model that treats staging as a layered, time-dependent map rather than a single static snapshot.

---

Dynamic staging: a new mental model for an old problem

If standard staging is a photograph, dynamic staging is a short film. It recognizes three axes that determine what you will detect and how you should act: anatomy, molecular phenotype, and time. Put differently, any staging or treatment decision should be informed by the intersection of three coordinates:

1. Anatomical completeness: which nodal stations have been sampled or imaged? Are internal iliac nodes included? What is the expected pattern of spread for the clinical scenario?
2. Molecular sensitivity: does the modality detect the phenotype the tumor currently expresses? For PSMA, how intense is the expression relative to detection thresholds and to potential therapeutic penetration?
3. Temporal modulation: what therapies have been given or are planned that will alter expression and distribution? When were the images obtained relative to those therapies?

A quick operational rule follows: high anatomical risk with low molecular signal requires nets; high molecular signal with limited anatomical access favors spotlights and darts. Most clinical situations fall between these extremes, which is why integration matters.

Concrete example: a patient with intermediate risk prostate cancer and negative conventional imaging undergoes preoperative PSMA-PET that shows no nodal uptake. Under a purely molecular logic you might omit extended dissection. Under anatomical logic you would perform an extended pelvic lymph node dissection including internal iliac nodes because those nodes can be positive in a large minority of cN0 cases. Dynamic staging reconciles these views: in a patient with risk features that make nodal metastasis plausible, a negative PSMA-PET before androgen deprivation should not automatically replace an extended template dissection. Conversely, if PSMA-PET after short-term androgen deprivation lights up specific pelvic nodes, that molecular information can allow targeted removal or focal radiotherapy, minimizing collateral harm.

This approach places a premium on two practical changes: the timing of molecular imaging and the deliberate inclusion of internal iliac nodes in surgical templates when the pretest probability of nodal disease is significant.

---

Operational playbook: harmonizing map and signal

Here are tools and decisions that implement the dynamic staging model in clinical practice. They are presented as a pragmatic playbook rather than dogma. The goal is to reduce both under-treatment and over-treatment by aligning anatomical nets and molecular spotlights.

1. Preoperative planning should combine risk stratification, PSMA-PET findings, and an anatomical checklist. If risk features predict a substantial nodal burden, plan to include internal iliac stations in the dissection even when PSMA is negative. Remember: internal iliac nodes may be the only positive nodal site in roughly one in five patients who appear node negative otherwise.

2. Use PSMA-based imaging to guide targeted interventions when it identifies discrete hotspots. When PSMA-PET shows limited pelvic uptake, consider targeted excision or focused radiation. When PSMA highlights multiple sites or extra-pelvic disease, prioritize systemic or PSMA-directed radionuclide therapies.

3. Be deliberate about timing of PSMA imaging relative to androgen deprivation therapy. Androgen deprivation increases PSMA expression and can reveal lesions otherwise below detection limits, which is useful when planning PSMA-directed systemic therapy. However, for anatomical staging that will guide immediate surgical decisions, pre-ADT imaging gives a baseline map of disease distribution before you change tumor biology. In both cases, the clinician should record the therapy timeline and interpret PSMA findings through that lens.

4. Consider intraoperative PSMA probes as an adjunct, not a replacement, for anatomical dissection. Fluorescent or gamma probes that detect PSMA can help find nodes that are small but PSMA-bright, improving surgical precision. But nodes that are anatomically involved and PSMA-dim may still require removal under a template approach.

5. Use multidisciplinary discussion to choose among options: extended dissection, targeted excision, focal radiotherapy, or PSMA-directed systemic therapy. The model is not that one tool is superior; it is that aligning the choice with the three axes yields better precision and fewer surprises.

Practical analogy: if you are mapping a city for a delivery service, you need both a street map and real-time traffic lights. The street map prevents blind alleys; the traffic lights tell you which routes are currently congested or closed. Ignoring either will produce delays or missed deliveries.

---

When the map must change: consequences for research and practice

If staging is dynamic, several research priorities follow. Clinical trials should stratify patients not only by baseline risk but by the timing of PSMA evaluations and by which nodal stations are sampled. Outcome studies that compare PSMA-directed strategies to template surgery must report whether internal iliac nodes were systematically assessed, because unassessed internal iliac involvement can bias results.

Operationally, surgical education must emphasize internal iliac anatomy as a standard component of representative pelvic lymph node dissection. Radiology and nuclear medicine must standardize reporting of PSMA studies with notation of prior or concurrent androgen deprivation. Finally, emerging PSMA-targeted intraoperative tools should be trialed as complements to extended dissection, not as substitutes unless prospective data demonstrate equivalence.

There is also an ethical dimension. Patients should understand that a negative PSMA scan does not guarantee absence of nodal disease if the disease is early or untreated. Shared decision making should weigh the morbidity of extended dissection against the risk of leaving anatomically localized nodal disease behind.

Precision is not only about better instruments; it is about better alignment between what the instrument measures and the clinical question at hand.

---

Key Takeaways

• Use anatomy and molecular imaging as complementary tools: plan pelvic nodal dissection that includes internal iliac stations when pretest probability is significant, even if PSMA-PET is negative.
• Interpret PSMA-PET through the lens of timing: androgen deprivation increases PSMA expression, so imaging before and after therapy answers different clinical questions.
• Use PSMA-positive findings to target therapy and minimize collateral damage, but do not let spotlights replace nets when the net is needed to establish representative staging.
• Consider intraoperative PSMA detection as an adjunct for precision, not a wholesale replacement for established anatomical templates.
• Bring clinicians from surgery, imaging, and radiation together early so that the chosen strategy aligns anatomy, molecular phenotype, and temporal context.

---

Conclusion: staging as choreography, not a snapshot

Prostate cancer care cannot be reduced to a binary contest between anatomy and molecular signal. The clinical truth is more interesting: disease is situated in space, expressed in molecules, and altered by time and therapy. Thinking in terms of nets and spotlights helps clinicians choose the right tool for the right question. But the real advance is to choreograph both instruments so that each compensates for the other's blind spots.

When a patient enters the clinic, ask two questions in sequence: what does the map say and what does the beacon show right now? Then ask a third: how will therapy change both the map and the beacon? Answering these three questions, and acting on the answers, converts staging from a single decision into a dynamic strategy. That is how we reduce surprises, spare harm, and find the disease wherever it decides to hide.